ProCE Banner Activity

Expert Guidance on Personalizing Treatment of CLL: Overcoming the Conundrum of Multiple New Agents

Multimedia
In this on-demand Webcast, John M. Burke, MD, reviews the most recent clinical data on new agents in both frontline and relapsed/refractory CLL.

Released: October 01, 2019

Expiration: September 29, 2020

Share

Faculty

John M. Burke

John M. Burke, MD

Associate Chair
US Oncology Hematology Research Program
Rocky Mountain Cancer Centers
Aurora, Colorado

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Pharmacyclics an AbbVie Company

Verastem Oncology

Partners

CLL Society

ProCE Banner

Learning Objectives

Faculty Disclosure

Primary Author

John M. Burke, MD

Associate Chair
US Oncology Hematology Research Program
Rocky Mountain Cancer Centers
Aurora, Colorado

John M. Burke, MD, has disclosed that he has received consulting fees from AbbVie, AstraZeneca, Bayer, Celgene, Genentech, Gilead, Tempus, and Seattle Genetics and fees for non-CME/CE services from Seattle Genetics.